Dexamethasone acetate is under clinical development by Oculis and currently in Phase III for Ocular Inflammation. According to GlobalData, Phase III drugs for Ocular Inflammation have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexamethasone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone acetate overview

Dexamethasone acetate (DexNP, OC-118, OCS-01) is under development for the treatment of macular edema, diabetic macular edema and post cataract operation inflammation and pain. The tehrapeutic candidate is formulated as eye drop suspension and administered through ophthalmic route of administration. It is a nanoparticle composed of gamma-cyclodextrin dexamethasone complex. Dexamethasone is synthetic glucocorticoids which target glucocorticoid receptors. The drug candidate is a complex of drug and cyclodextrin nanoparticle developed based on solubilizing nano-particle (SNP) drug-delivery technology. It was also under development of posterior and intermediate uveitis, glaucoma and ocular inflammation after surgery.

Oculis overview

Oculis operates as a clinical-stage biopharmaceutical company that offers topical treatments for acute, chronic back and front-of-the-eye ophthalmic diseases. Its pipeline product portfolio includes OCS-01 a topical treatment for diabetic macular edema, inflammation and pain, and cystoid macular edema; OCS-02 for uveitis and dry eye; OCS-05 for treating acute optic neuritis, glaucoma, and neurotrophic keratitis. Its Optireach helps in solubilizing technology to improve the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including anterior and posterior segments. The company has research operations in Reykjavik, Iceland. Oculis is headquartered in Lausanne, Waadt, Switzerland.

For a complete picture of Dexamethasone acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.